VXRT - Vaxart, Inc.
0.7100
After hours: 4:35PM EDT
| Previous Close | 0.7300 |
| Open | 0.7210 |
| Bid | 0.7022 x 2900 |
| Ask | 0.7400 x 3200 |
| Day's Range | 0.7020 - 0.7400 |
| 52 Week Range | 0.6000 - 7.6000 |
| Volume | 122,603 |
| Avg. Volume | 1,087,096 |
| Market Cap | 6.579M |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-11-09 |
| 1y Target Est | 5.00 |
- Business Wire•11 days ago
Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
- $13 million raised in 1H19 -
- Simply Wall St.•13 days ago
Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. The flip side...
- Business Wire•last month
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial. “We are delighted to start the randomized portion of the bivalent norovirus phase 1b trial,” said David Taylor, M.D., chief medical officer of Vaxart. Norovirus is the leading cause of foodborne illness in the United States and causes significant morbidity and mortality in older adults and the very young.
- Business Wire•last month
Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist at Vaxart, will present preclinical data in a poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases showing that Vaxart’s oral quadrivalent influenza vaccine conferred 100% protection against a lethal H5N1 avian influenza challenge in ferrets.
- Business Wire•last month
Vaxart Announces Pricing of Underwritten Public Offering
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 8,165,455 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at an effective price to the public of $1.10 per share and accompanying common warrant. Each common warrant will have an exercise price of $1.10 per share, be exercisable immediately and will expire five years from the date of issuance.
- Business Wire•2 months ago
Vaxart to Present at Global Medical Meetings in April
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.
- Business Wire•2 months ago
Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine. The Vaxart bivalent norovirus vaccine consists of an oral norovirus GI.1 vaccine and an oral norovirus GII.4 vaccine administered concurrently by tablet. The bivalent norovirus Phase 1b trial consists of two parts, an open-label lead-in phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to start in April, subject to final review by the FDA.
- Business Wire•2 months ago
Vaxart Announces Closing of Registered Direct Offering of Common Stock
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million, before deducting placement agent fees and estimated offering expenses. The securities described above were offered by Vaxart pursuant to a registration statement on Form S-3 (File No. 333-228910) previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on March 15, 2019.
- ACCESSWIRE•2 months ago
Watch These Four Healthcare Stocks Set The Pace On Tuesday
Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
- Business Wire•2 months ago
Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock, at a purchase price of $2.50 per share, for aggregate gross proceeds of $3 million. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The shares of common stock are being offered by Vaxart pursuant to a “shelf” registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").
- Business Wire•2 months ago
Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” said Wouter Latour, M.D., chief executive officer of Vaxart.
- Business Wire•3 months ago
Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019
- Business Wire•6 months ago
Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California. Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness.
- Business Wire•6 months ago
Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Start of Norovirus Vaccine Trials Delayed to 1H 2019 Due to Manufacturing Issue
- InvestorPlace•7 months ago
Vaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain
Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.
- Zacks•7 months ago
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
- ACCESSWIRE•7 months ago
Today’s Research Reports on Stocks to Watch: Guardant Health and Vaxart
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.
- Business Wire•7 months ago
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018. “These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%.
- Business Wire•9 months ago
Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.
- Business Wire•10 months ago
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus oral tablet vaccine in the Journal of Clinical Investigation Insight. The paper by Leesun, Kim, et al., “Safety and immunogenicity of an oral tablet norovirus vaccine, a phase 1 randomized, placebo-controlled trial”, highlights the benign safety profile of the Vaxart vaccine and describes the generation of robust systemic and mucosal immune responses, including mucosal IgA, memory B cells, and serum blocking antibody titers (BT50), all potential correlates of protection.
- Business Wire•11 months ago
Oral RSV Vaccine - Preclinical Data Published in Vaccine
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral F-protein based Respiratory Syncytial Virus (RSV-F) vaccine. The findings were published in the most recent online version of Vaccine (Joyce C. et al., “Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats”). As described in the article, the oral RSV-F vaccine candidate provided complete sterilizing protection against RSV infection in the cotton rat challenge model at the target dose.
- Business Wire•11 months ago
Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel dosed topically twice daily in 218 subjects for the treatment of condyloma, or anogenital warts. The primary efficacy endpoint was defined as complete clearance of baseline condyloma by week 16.
- Business Wire•last year
Vaxart to Present at the Jefferies 2018 Global Healthcare Conference
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018, at 1:00 p.m. EST in New York. A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.
- Business Wire•last year
Vaxart to Present at ASM Microbe 2018
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.
